Pharmacokinetics of Cotadutide in Participants With Hepatic Impairment

This study will consist of four cohorts (Cohort 1, Cohort 2, Cohort 3, and Cohort 4). Participants will be assigned to each of the cohorts as per Child-Pugh classification: * Cohort 1: Mild hepatic impairment (Child-Pugh A), cotadutide 50 μg * Cohort 2: Moderate hepatic impairment (Child-Pugh B), cotadutide 50 μg * Cohort 3: Severe hepatic impairment (Child-Pugh C), cotadutide 50 μg * Cohort 4: Normal hepatic function, cotadutide 50 μg